TriSalus posts third-quarter revenue gain
WESTMINSTER — TriSalus Life Sciences Inc. (Nasdaq: TLSI), a Westminster-based company that develops treatments for pancreatic and liver tumors, reported higher revenue for the third quarter ended Sept. 30.
TriSalus recorded revenue of $5.2 million, up 32% from $3.9 million for the same period a year ago. The company recorded a net loss attributable to common stockholders of $1.7 million, compared with $8 million in the third quarter of 2023.
Its operating loss increased to $18.4 million from $8.1 million a year ago.
TriSalus reported cash and cash equivalents of $21.4 million. Assets totaled $33.6 million, with total liabilities at $25.1 million.
SPONSORED CONTENT
TriSalus in August completed a merger with special-purpose acquisition company MedTech Acquisition Corp., significantly boosting the company’s cash reserves.
WESTMINSTER — TriSalus Life Sciences Inc. (Nasdaq: TLSI), a Westminster-based company that develops treatments for pancreatic and liver tumors, reported higher revenue for the third quarter ended Sept. 30.
TriSalus recorded revenue of $5.2 million, up 32% from $3.9 million for the same period a year ago. The company recorded a net loss attributable to common stockholders of $1.7 million, compared with $8 million in the third quarter of 2023.
Its operating loss increased to $18.4 million from $8.1 million a year ago.
TriSalus reported cash and cash equivalents of $21.4 million. Assets totaled $33.6 million, with total liabilities at $25.1 million.
TriSalus in…
Related Posts
-
Enliven Therapeutics finished the third quarter with $292 million in cash, which, the company said,…
-
Biodesix Inc. (Nasdaq: BDSX), a life-sciences company that specializes in developing tools to detect lung…
-
Edgewise Therapeutics Inc., a Boulder-based muscle disease biopharmaceutical company, increased its research and development spending…
-
Arca Biopharma has completed its merger with Oruka Therapeutics Inc.